Risk management: Pharma, life sciences and healthcare must think ahead of regulatory change
In environments defined by uncertainty, proactive risk management becomes more than a tactic; it’s a way of operating effectively. Even so, with such a broad range of changes taking shape, it can be difficult to know where to start and how to weave risk management into the fabric of an organization.
Case in point: 2025 saw the Government of Ontario announcing plans to expand the scope of practice for various regulated health professionals. This proposed enhanced scope includes everyone from physicians and allied healthcare professionals to pharmacists, optometrists and psychologists. Meanwhile in British Columbia, new health profession legislation came into force, fundamentally restructuring the regulatory framework, establishing new regulatory bodies, and imposing many additional obligations on health professionals. Other provinces are also seeing similar, broadly based reforms. For example, Alberta is engaged in a major restructuring of its public health sector including introducing legislation to enable more public-private provision of medical services.
This comes on the heels of the Government of Canada’s efforts to reduce regulatory burdens in the life sciences specifically. Health Canada and the Public Health Agency of Canada have introduced 42 initiatives in recent years, and each one ladders up to one of the government’s five thematic goals:
- Increasing international alignment and reducing trade barriers
- Improving stakeholder experience and service delivery
- Risk-based regulating
- Streamlining regulations, simplifying rules, and enhancing flexibility
- Enabling new products and technologies
These themes cut a wide swath across pharma and life sciences, touching many elements of the sector. Importantly, they also echo the general shift towards streamlining and modernizing processes within current health profession regulatory frameworks. The combined effect? Many aspects of these industries could be impacted in some way, including areas such as:
- Professional duties and associated potential civil and professional liabilities for health professionals and clinics
- Pre-market requirements, approval processes, labelling
- Post-market standards for pharma and life sciences
The Health Canada initiatives have been designed to create a regulatory landscape that balances robust protection of public health and safety and efficacy with economic competitiveness and innovation. The changes to professional regulation are more complicated, as the provincial schemes take different approaches to balancing patient rights with professional independence. Accordingly, pharma and life sciences organizations must proactively understand how regulatory requirements will change as new initiatives are completed, and updated regulations come online.
Pharma and life sciences organizations at every stage of the growth journey will need to get, and stay, ahead of these regulatory shifts. This includes businesses from every corner of the sector:
- Mid-sized, scaling, or emerging biotechs and medtechs
- Medium and large pharma companies
- Private healthcare operators
- Digital health companies
- Private equity investors
All the more reason to build regulatory risk management muscle into daily operations now.
Continuous innovation, continuous compliance
The pandemic revealed just how quickly innovation can happen when focused time is directed toward it. In the years since, technology has continued to change at a previously unimaginable pace. While this creates new opportunities for pharma, life sciences and healthcare to innovate and expand, it also widens the cavernous gap between research, development, and Canada’s regulatory regime.
As Alexis Kerr, Partner, Norton Rose Fulbright Canada told Lexpert: “Even though AI-specific legislation is still under development in Canada, AI is not a lawless space.”1 AI holds new possibilities for pharma and life sciences organizations creating novel therapies, drugs, devices, healthcare paradigms (such as virtual care), and business models. It is one more factor helping high-tech, high-innovation ideas to flourish within the sector. That confluence of concepts, products, and services brings additional questions about not only how to develop, test, and approve these offerings – but how to do so when the science is moving more quickly than the regulations intended to govern it. What’s more: market entry isn’t the end of compliance. It’s just the beginning.
Organizations don’t get a free pass not to comply simply because regulatory machinery lags behind the pace of innovation. This leaves many pharma and life sciences leaders looking to apply rules in regulatory situations they simply weren’t designed for. This adds additional complexity for any organization looking to balance speed-to-market with regulatory compliance. This dynamic has a particular impact on emerging and evolving focus areas such as:
Digital health
In Canada, digital health spans health technologies that improve access to healthcare information, facilitate diagnosis and treatment, and improve patient access to care. These data-driven healthcare solutions help stakeholders (patients, healthcare providers, and others) communicate and connect seamlessly through technology. They bring both broad, system-wide improvements and individual-level, personalized medicine (think targeted therapies; innovative devices enabling improved diagnostics, surveillance and prevention; and enhanced communication and systems integration).
Innovation within digital health raises regulatory considerations around:
- Data protection and privacy, patient safety, professional regulatory requirements, public policy, cybersecurity, and civil liability risks.
- Not to mention the compliance risks triggered by the cross-border data transfers which are a feature of multi-jurisdictional health technology systems.
Gene therapy
In recent years, the incredible promise of gene therapy has become a reality, with multiple products entering the Canadian market. That includes CAR-T therapy (a gene therapy for treating blood cancers) and AAV-based therapy (for restoring gene function). Canada doesn’t have a distinct legislative framework for gene therapy products. Instead, they’re subject to the same regulatory provisions as other drugs under the Food and Drugs Act and Food and Drug Regulations.
Innovation within gene therapy products raises regulatory considerations around:
- Data protection (new drugs are eligible for data protection if considered an innovative drug; one that contains a medicinal ingredient not previously approved in Canada);
- Patent protection (subject to the same legislation as other patented products in Canada);
- Patent litigation (with the first case concerning a gene therapy patent initiated in 2022);
- As well as a host of emerging issues including gene editing technology and market access.
Biometric data
The explosive growth of AI technology has fed an equally rapid expansion of biometric data use. This entails measurable and unique human characteristics, such as fingerprints or keystroke patterns, to identify or authenticate individuals. Wearable commercial health tech used by the weekend warrior. Innovative AI scribes rolled out in family medicine offices. Remote monitoring in long-term care facilities. Pharmaceutical research analytics. Use cases abound as biometrics cement themselves in all parts of the health sector lifecycle. And regulators are paying attention. In 2025, the Office of the Privacy Commissioner of Canada released its updated guidance on using biometric information. Similar developments are shaping provincial guidance in British Columbia and Ontario.
Innovation within biometric data raises regulatory considerations around:
- New privacy compliance obligations as well as potential penalties for contravention (i.e., administrative and monetary penalties under provincial laws);
- Sensitivities and requirements around using of personal information;
- Appropriate practice guidelines that ensure collection of biometric information serves and appropriate use;
- Consent matters;
- Personal Information Protection and Electronic Documents Act compliance considerations.
Modernizing clinical trials for current realities
In a move to simplify existing rules and establish a modern framework for flexible, risk-based oversight: Health Canada announced draft Clinical Trial Regulations at the end of 2025. The refresh is geared to better support innovative trials, reduce the regulatory burden, and enhance participant access and safety.
What stands out?
The draft is part of a broader Health Canada Clinical Trials Regulatory Modernization initiative. It builds on regulatory flexibilities piloted during the COVID-19 pandemic, as well as stakeholder feedback and consultations. It’s also said to be more flexible and internationally aligned – which could help attract global investment, increase research capacity, and expand access to new therapies.
What is new?
The update keeps much of the current regulatory framework in place. It also adds new regulatory features:
- Shift to regulating clinical trial conduct (Health Canada would retain these powers while gaining direct [flexible and risk-based] oversight over conduct throughout the trial’s lifecycle)
- Review process improvements and extended timelines
- Increase in flexibility around innovative trial design
- Imposition of terms and conditions on a clinical trial authorization at any point to mitigate risk or address uncertainties
- Use of a national research ethics board to approve and protect informed consent across multiple trial sites in Canada
- Obligation for post-trial reporting to enhance patient safety over the long term
What happens next?
The initial consultation has wrapped up. Once final, the regulations would come into force 12 months after being published in the Canada Gazette.
Virtual care and regulatory dynamics
All things virtual began accelerating at an exponential rate in 2020 – and that includes virtual care. It’s been five years since the Information and Privacy Commissioner of Ontario unveiled new guidance for virtual care providers, with specific steps to enhance privacy and security. As Norton Rose Fulbright Canada’s Sara Levine wrote at the time: “Most of the same principles exist under the privacy laws of other provinces, and thus the guidance will be useful for health professionals no matter where they practice.”2
Specifically, the Ontario guidance reinforced the importance of carrying out privacy impact assessments, implementing consistent virtual healthcare policies, and implement a framework to monitor, assess and mitigate security risks (including breach protocols). Technology – and its impact on virtual care – has only continued to adapt and improve. With that evolution comes an increasing need to understand how personal health data is used and mitigate risks that haven’t existed in the past. From a healthcare perspective in Canada, this requires stakeholders to consider key legal and regulatory issues such as:
- Data privacy and cybersecurity, including appropriate data management systems
- Informed consent from patients and other participants in the platform
- Cross-border transmission of personal health information
- Liability for use of the digital platform
- Intellectual property ownership and data governance
Points on pricing: Canadian complexity amid downward and upward pressure
Price complexity isn’t new for Canada’s pharma and life sciences sectors. It is, however, evolving in line with regulatory shifts at home, and abroad.
Heading into 2026, Canadian drug manufacturers found themselves walking a tightrope to address new foreign and domestic drug pricing policies. As Norton Rose Fulbright’s Kristin Wall and Sarah Pennington explained in Navigating US most-favored-nation prescription drug pricing in Canada:
- In May 2025, US policymakers explored a “most-favored-nation (MFN)” approach to prescription drug pricing.
- Such proposals could place pressure on countries (including Canada) to increase prescription drug prices to align more closely with historically higher US prices.
- Canada is implementing its own new drug pricing policies that place downward pressure on already lower Canadian prices. For example, the Patented Medicine Prices Review Board's (PMPRB) new drug pricing guidelines took effect in 2026. The PMPRB’s guidelines benchmark Canadian drug prices against 11 other countries (most notably, excluding the US).
Differential pricing around the world has historically been managed by confidential net prices. If the MFN policy succeeds in benchmarking against net prices, this could cause a seismic shift in the practice of comparator/reference drug pricing.
Paradoxically, while the MFN policy asks countries such as Canada to pay their fair share of global pharmaceutical R&D by increasing drug prices, other US initiatives strive to benefit from Canada’s lower drug prices. Notably, US law on the Importation of Prescription Drugs (US Importation Rule) sets out a process whereby states can submit proposals to the US Food and Drug Administration to import eligible (lower cost) drugs approved by Health Canada.
Operating – and thriving – in “The grey zone”
If pharma and life sciences were ever in a proverbial grey zone, this is it. At a macro level, the sector is facing massive uncertainty. Dig deeper, though, and the disruptors reshaping economies and markets are creating corresponding impacts specific to stakeholders in this sector.
That’s cultivating a system defined by regulatory queries – some tied to the so-called “grey market” itself.
For example, an individual or organization might look to capitalize on availability of a given drug and sell it online or through other digital channels for an off-label purpose. This opens businesses up to considerable risk, oftentimes stemming from confusion over regulatory requirements. In these cases, it is possible to come into compliance and continue the business as a going concern. But getting there requires clear regulatory risk management, understanding, and planning.
More broadly, though, the grey zone stretches into unclear aspects of the sector where disconnects exist between what’s been approved, what’s been regulated, and how businesses can align innovative approaches with often complicated requirements.
At the same time, patients are becoming increasingly more involved in their own healthcare. More informed, and fuelled by a wealth of readily available online information, patients may want companies to seek approval into new treatment territory, only to find the regulator simply isn’t there yet.
With so many moving parts, it can be hard to know how to advance without falling out of step on regulation.
By the numbers: Questions PE, VC and other investors should ask
Canada continues to be a top destination for capital investment. Research shows Canadian CEOs rank their home country first among other investment destinations. Meanwhile, global leaders peg Canada as their second destination of choice.3 That’s sound optimism despite ongoing volatility. Canadian pharma and life sciences could certainly stand to gain from that intention.
This particular environment, and the heavily regulated nature of the industry, requires investors to think through specific questions in order to manage risk and achieve deal goals. Companies (whether issuers or investors) must understand the risks of non-compliance with regulation, potential risk to the company being acquired, and the safeguards and regulatory compliance mechanisms in place before moving ahead.
About our regulatory practice
Canadian organizations operating in highly regulated environments need advisors who can anticipate change, cut through complexity, and support confident decision making when it matters most. We help clients stay ahead of regulatory reform, manage compliance risk across jurisdictions, and engage regulators effectively – before issues escalate.
With more than 100 regulatory lawyers across Canada, our practice brings scale, insight, and credibility that set us apart:
- National coverage with deep local understanding. Our teams across the country navigate federal and provincial regimes, manage jurisdictional nuance, and coordinate seamlessly with our global colleagues on cross-border matters.
- Integrated, cross-disciplinary support. Clients benefit from a coordinated bench spanning regulatory, litigation, privacy, IP, corporate, and transactional – reflecting how regulatory, legal, and operational issues intersect in practice.
- Proactive regulatory intelligence. We track and interpret high-volume regulatory change, share insight across the country, and provide timely guidance that helps clients plan early and act decisively.
- Regulatory insight shaped from the inside. Our senior advisors bring first-hand government experience, giving clients a clear understanding of how regulatory decisions are made – and how to engage regulators with confidence and credibility.
Navigate regulatory complexity with confidence. Contact our regulatory team today.
Footnotes
-
Hendry, Mallory, ‘AI tools in healthcare sector rife with legal and ethical risk that must be mitigated’, Lexpert, 17 June 2024 ↩
-
Barry, Veronique et al. Norton Rose Fulbright: International Comparative Legal Guides. Digital Health, 2025, Sixth Edition. ↩
Your trusted regulatory authority for clarity and compliance.